Skip to content

PhaseBio Pharmaceuticals, Inc.

CIK 0001169245

← back to feed
Revenue (TTM)
$11M
+3,284.7% YoY Q2 Aug 2022
Net Income (TTM)
−$88.41M
−33.0% YoY Q2 Aug 2022
EPS Diluted (TTM)
−$1.83
+12.1% YoY Q2 Aug 2022
Gross Margin
—
Q2 Aug 2022
Operating Margin
-847.1%
Q2 Aug 2022
Net Margin
-803.9%
Q2 Aug 2022
Free Cash Flow (TTM)
−$66.47M
Q2 Aug 2022
Cash
$7.8M
Q2 Aug 2022
Total Debt
$4.07M
Q2 Aug 2022
Shares Outstanding
49.86M sh
Q2 Aug 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings